Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

503 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cell-free and concentrated ascites reinfusion therapy versus large-volume paracentesis for the treatment of cirrhotic patients with refractory ascites: A multicenter prospective observational study.
Hanai T, Kawaratani H, Nagano J, Suii H, Sakamaki A, Arase Y, Nakanishi H, Kogiso T, Okubo T, Miwa T, Shimizu S, Hige S, Atsukawa M, Shimizu M, Kurosaki M, Terai S, Kagawa T, Tokushige K, Yoshiji H. Hanai T, et al. Among authors: kurosaki m. Hepatol Res. 2023 Mar;53(3):238-246. doi: 10.1111/hepr.13860. Epub 2022 Dec 3. Hepatol Res. 2023. PMID: 36433862
The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy.
Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Komatsu N, Umeda N, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Itakura J, Asahina Y, Miyake S, Enomoto N, Izumi N. Kurosaki M, et al. J Hepatol. 2008 May;48(5):736-42. doi: 10.1016/j.jhep.2007.12.025. Epub 2008 Feb 26. J Hepatol. 2008. PMID: 18329125
A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis.
Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, Tamaki N, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Ikeda H, Itakura J, Takahashi Y, Asahina Y, Higaki M, Enomoto N, Izumi N. Kurosaki M, et al. Hepatol Res. 2010 Apr;40(4):251-60. doi: 10.1111/j.1872-034X.2009.00607.x. Epub 2010 Jan 11. Hepatol Res. 2010. PMID: 20070391
Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy.
Kurosaki M, Hosokawa T, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, Tamaki N, Ueda K, Tsuchiya K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, Izumi N. Kurosaki M, et al. Hepatol Res. 2010 Sep;40(9):870-7. doi: 10.1111/j.1872-034X.2010.00692.x. Hepatol Res. 2010. PMID: 20887591
Changes in hepatitis C viral load during first 14 days can predict the undetectable time point of serum viral load by pegylated interferon and ribavirin therapy.
Itakura J, Asahina Y, Tamaki N, Hirayama I, Yasui Y, Tanaka T, Sato M, Ueda K, Kuzuya T, Tsuchiya K, Nakanishi H, Kurosaki M, Gabriel GS, Schneider GJ, Izumi N. Itakura J, et al. Among authors: kurosaki m. Hepatol Res. 2011 Mar;41(3):217-24. doi: 10.1111/j.1872-034X.2010.00768.x. Hepatol Res. 2011. PMID: 21338453
503 results